Adherex Technologies (NASDAQ:FENC) Issues Earnings Results, Beats Expectations By $0.03 EPS

Adherex Technologies (NASDAQ:FENC) announced its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, Zacks reports. Adherex Technologies had a negative net margin of 17.12% and a negative return on equity of 43.87%. The firm had revenue of $17.87 million during the quarter, compared to analysts’ expectations of $16.21 million.

Here are the key takeaways from Adherex Technologies’ conference call:

• PEDMARK net product sales rose 78% year over year to $17.1 million in Q2 2026, marking the company’s seventh consecutive quarter of growth. Non-GAAP adjusted EBITDA improved to $2.8 million from a $1.2 million loss a year ago.
• Commercial momentum accelerated, with Q2 demand up double digits sequentially, record patient enrollments and infusions, and a 280% increase in sales calls. July produced all-time highs for completed infusions, new enrollments, active patients, and new customers, while the expanded sales force now reaches roughly 5,000 targets.
• Medical and clinical efforts are expanding, including three actively accruing investigator-sponsored studies and an upcoming oral presentation of Japan’s STS-J01 trial data at SIOP 2026. Management said maturing data could support future label expansions and stronger NCCN recommendations, while discussions with potential Japanese and Asia-Pacific partners continue.
• Operating expenses excluding stock-based compensation increased to approximately $13.6 million, driven largely by higher commercial headcount and marketing investments. Management expects cash to decline in Q3 due to customer collection cycles, although it anticipates positive cash generation in Q4 and year-end cash.

Adherex Technologies Trading Up 16.8%

Adherex Technologies stock opened at $12.78 on Wednesday. Adherex Technologies has a 52 week low of $5.65 and a 52 week high of $13.25. The stock has a market cap of $448.07 million, a P/E ratio of -44.07 and a beta of 1.09. The stock has a 50 day moving average of $10.08 and a 200-day moving average of $8.54.

Institutional Trading of Adherex Technologies

A hedge fund recently bought a new position in Adherex Technologies stock. AQR Capital Management LLC bought a new stake in Adherex Technologies Inc. (NASDAQ:FENC) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 10,897 shares of the company’s stock, valued at approximately $66,000. Institutional investors and hedge funds own 55.51% of the company’s stock.

Wall Street Analyst Weigh In

FENC has been the topic of a number of recent research reports. HC Wainwright boosted their price objective on Adherex Technologies from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adherex Technologies in a research note on Friday, July 17th. Zacks Research upgraded Adherex Technologies from a “strong sell” rating to a “hold” rating in a report on Monday, May 25th. Wedbush reiterated an “outperform” rating and set a $13.00 price objective on shares of Adherex Technologies in a research note on Thursday, April 16th. Finally, Wall Street Zen raised shares of Adherex Technologies from a “hold” rating to a “strong-buy” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Adherex Technologies presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

About Adherex Technologies

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc and changed its name to Fennec Pharmaceuticals Inc in September 2014. Fennec Pharmaceuticals Inc was founded in 1996 and is based in Research Triangle Park, North Carolina.